Download MendeleyInhibition of Both Focal Adhesion Kinase and Fibroblast Growth Factor Receptor 2 Pathways Induces Anti-Tumor and Anti-Angiogenic Activities.
Dao, P., Jarray, R., Smith, N., Lepelletier, Y., Le Coq, J., Lietha, D., Hadj-Slimane, R., Herbeuval, J.P., Garbay, C., Raynaud, F., Chen, H.(2014) Cancer Lett 348: 88
- PubMed: 24657306
- DOI: https://doi.org/10.1016/j.canlet.2014.03.007
- Primary Citation of Related Structures:
4C7T - PubMed Abstract:
FAK and FGFR2 signaling pathways play important roles in cancer development, progression and tumor angiogenesis. PHM16 is a novel ATP competitive inhibitor of FAK and FGFR2. To evaluate the therapeutic efficacy of this agent, we examined its anti-angiogenic effect in HUVEC and its anti-tumor effect in different cancer cell lines. We showed PHM16 inhibited endothelial cell viability, adherence and tube formation along with the added ability to induce endothelial cell apoptosis. This compound significantly delayed tumor cell growth. Together, these data showed that inhibition of both FAK and FGFR2 signaling pathways can enhance anti-tumor and anti-angiogenic activities.
Organizational Affiliation:
CNRS, UMR8601, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CBNIT, Université Paris Descartes, PRES Sorbonne Paris Cité, UFR Biomédicale, 45 rue des Saints-Pères, 75270 Paris Cedex 06, France.
